Alnylam (NASDAQ: ALNY) is developing a novel class of drugs based on RNA interference, and is pursuing a range of targets in genetic medicine, cardio-metabolic disease, and hepatic infectious disease.
| Headquarters | Cambridge, MA |
| Website | www.alnylam.com |
| Pipeline | FDA-approved (US) |